SecBot SecBot
8-K ·Filed Nov 12, 2026

PRAX

Praxis Precision Medicines, Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed4d 8h ago SEC0001689548-26-000091
8-K context-dependent: Items 7.01, 8.01
Actionable Insight • Neutral

Key catalysts over next 12 months: relutrigine PDUFA Dec 27, 2026; ulixacaltamide PDUFA Jan 29, 2027; EMERALD broad DEE topline 4Q26; EMBRAVE3 elsunersen topline 2027; PRAX-215 Phase 1 readout 2027. Monitor FDA advisory committee schedules and label breadth for both launches.

DirectionNeutral
Confidencehigh
Horizonweeks

Drugs in focus

PRAX drug pipeline →

relutrigine

▲ Bullish Named in this 8-K
Impact
Phase
Filed/PDUFA (NDA under priority review)
Time to market
PDUFA target action date is December 27, 2026. If approved, a U.S. launch could follow in early 2027.
Next catalyst
PDUFA date · Dec 27, 2026 40d

What to watchThe next binary catalyst is the PDUFA decision on December 27, 2026, roughly six weeks away. Approval would likely drive a significant re-rating given no approved therapies exist for SCN2A/SCN8A DEEs, while a CRL would pressure the stock. Also watch for EMERALD study topline results in broad DEEs (Q4 2026), which could expand the addressable market.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$328.13
T+0 close · Nov 12, 2026 · via day close
Latest settled
−5.44%
T+1 · $310.27
Vs SPY
−3.53%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $328.13entry
  2. T+1 · 18h ago −5.44%α −3.53% · $310.27
  3. T+5 · in 3d Pending
  4. T+20 · in 27d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Praxis Precision Medicines hosted an Investor Day on November 12, 2026, presenting commercial launch plans for two upcoming PDUFA dates in late 2026/early 2027 (relutrigine for SCN2A/SCN8A DEE and ulixacaltamide for essential tremor), updated clinical data including 86% seizure reduction at 18 months for relutrigine and positive FDA sensitivity analyses for ulixacaltamide, and an expanded pipeline across movement disorders, pain, epilepsy, and antisense oligonucleotide programs. The filing is a routine business update with no financial results; all revenue projections are analyst consensus or illustrative scenarios, not company guidance.

Key Facts

  • Relutrigine PDUFA date December 27, 2026 for SCN2A/SCN8A DEE; ulixacaltamide PDUFA date January 29, 2027 for essential tremor
  • Updated relutrigine open-label extension data showed 86% reduction in motor seizures from baseline at 18 months
  • Ulixacaltamide ESSENTIAL3 sensitivity analyses requested by FDA were consistent with primary result; 95-week long-term safety data showed durable ADL improvement
  • Company plans to initiate ulixacaltamide studies in Parkinson's disease, restless legs syndrome and autism spectrum disorder in 2027
  • Two new T-type calcium channel inhibitors (PRAX-050, PRAX-051) expected to enter first-in-human studies in first half of 2027
  • Pain pipeline introduced: PRAX-215 (pan-NaV) in Phase 1 with 2027 readout; PRAX-110 (NaV1.8-biased) IND submission in 2027
  • PRAX-206 (KCNT1 inhibitor) planned to enter clinic in early 2027
  • Elsunersen (PRAX-222) pivotal EMBRAVE3 study topline expected in 2027 with NDA filing
  • Six preclinical ASO programs advancing within Solidus platform
  • Ulixacaltamide pricing corridor $50K-$100K WAC per year; relutrigine pricing corridor $400K-$600K WAC per year

Financial Impact

No financial results reported; illustrative peak sales scenarios presented: ulixacaltamide $1B at 1% penetration of 2M ET patients; relutrigine $1B peak from SCN2A/8A alone, $5B combined with broad DEE. Consensus analyst sales for Praxis portfolio projected at $13.5B by 2035E assuming approvals.

revenue

Risk Factors

  • Regulatory approval and label scope for relutrigine and ulixacaltamide are not guaranteed
  • Commercial execution risk: both launches are first-of-kind for the company with no prior revenue
  • Pricing and reimbursement uncertainty for both products, particularly step therapy and prior authorization requirements
  • Clinical trial risks for pipeline programs (EMERALD broad DEE, line extensions, pain programs) are early-stage with no efficacy data yet
  • Competition from existing generic therapies and potential future entrants in essential tremor and DEE markets

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001689548-26-000091
Document: prax-20261112.htm0001689548-26-000091
Document: 0001689548-26-000091-index-headers.html0001689548-26-000091
Document: 0001689548-26-000091-index.html0001689548-26-000091
Document: 0001689548-26-000091.txt0001689548-26-000091

Track record

16 reports on PRAX

Performance horizon

5 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +15.73% at T+60 after the Jun 29, 2026 report. 6 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $317.69 Now $310.27 +2.34% settles Feb 12
  2. Nov 12, 20264d ago 8-K Neutral 4/10 Viewing Entry $328.13 Now $310.27 −5.44% settles Feb 11
  3. Nov 9, 20267d ago Press Release Neutral 4/10 Entry $332.97 Now $310.27 −6.82% settles Feb 5
  4. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $262.59 Now $310.27 +18.16% settles Feb 3
  5. Nov 4, 202612d ago Press Release Neutral 1/10 Entry $262.59 Now $310.27 +18.16% settles Feb 3
  6. Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $288.62 Now $310.27 +7.50% settles Jan 27
  7. Jun 29, 202620w ago 8-K Bearish 6/10 Entry $334.79 to $282.12 Now $310.27 +7.32% ▲ +15.73% +18.55% vs SPY
  8. Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $247.98 to $351.81 Now $310.27 +25.12% ▲ +41.87% +37.47% vs SPY
  9. Jun 2, 202623w ago Press Release Neutral 1/10 Entry $278.93 to $367.85 Now $310.27 +11.24% ▲ +31.88% +29.38% vs SPY
  10. May 7, 202627w ago Press Release Bullish 8/10 Entry $333.28 to $305.51 Now $310.27 −6.90% ▼ −8.33% −12.17% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens in 8h 18m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026